X4 Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Positive results from completed Phase 2 study of mavorixafor in chronic neutropenia (CN) announced todayPivotal Phase 3 trial of mavorixafor in ...
Business Insider23h
X4 Pharmaceuticals Announces Positive Results from Completed Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN)
The larger Phase 3 mavorixafor CN trial will expand on these data ... The level of circulating neutrophils is typically measured by drawing blood to determine the absolute neutrophil count (ANC).